Emerging research suggest Retatru tide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could represent a notable development for obesity treatment. Initial human https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026